Developing global, high-value products for patients with significant unmet medical needs in niche indications
Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.
A potential treatment for patients with IgA nephropathy at risk of developing ESRD.
Calliditas shortlisted in two categories at the European Lifestars Awards: Post-IPO Equity Raise of the Year and Deal of the Year (<£500m)
On May 14, 2020, at 07:00 CEST, Calliditas Therapeutics published its interim report for the first quarter 2020.
Calliditas Therapeutics AB
Kungsbron 1, C8
SE-111 22 Stockholm
Company number: 556659-9766
© Calliditas Therapeutics AB 2020